GLAUCOMA RESEARCH FOUNDATION

EIN: 942495035 501(c)(3) Medical Research

SAN FRANCISCO, CA

Total Revenue
$7,188,147
Total Expenses
$6,983,043
Total Assets
$14,638,577
Net Assets
$13,533,922
🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Sign In — Free (10 views/day)

Financial Trends

Organization Details

Formation Year
1978
Legal Domicile
CA
Principal Officer
THOMAS M BRUNNER
Phone
4159863162
Tax Period
2023-07-01 to 2024-06-30

GLAUCOMA RESEARCH FOUNDATION, founded in 1978, is a community nonprofit in the Medical Research sector that reported $7.2M in total revenue in fiscal year 2023. Revenue grew 11% year-over-year, indicating healthy expansion.

Mission

Cure Glaucoma and restore vision through innovative research.

Program Service Accomplishments

Program 1
Expenses: $5,950,391

THE ORGANIZATION PROMOTES AND SUPPORTS RESEARCH AND EDUCATION CONCERNING THE CAUSES AND TREATMENT OF GLAUCOMA. IT HAS BEEN A LEADER IN COLLABORATIVE RESEARCH THROUGH THE LANDMARK MULTI-CENTER NORMAL...

Read more

THE ORGANIZATION PROMOTES AND SUPPORTS RESEARCH AND EDUCATION CONCERNING THE CAUSES AND TREATMENT OF GLAUCOMA. IT HAS BEEN A LEADER IN COLLABORATIVE RESEARCH THROUGH THE LANDMARK MULTI-CENTER NORMAL TENSION GLAUCOMA STUDY WHICH TRANSFORMED GLAUCOMA TREATMENT, AS WELL AS THE CREATION OF THE "CATALYST FOR A CURE" (CFC). THIS UNIQUE RESEARCH MODEL BRINGS TOGETHER SCIENTISTS FROM DIFFERENT DISCIPLINES TO WORK TOGETHER TO UNDERSTAND GLAUCOMA AND FIND WAYS TO IMPROVE TREATMENT AND FIND A CURE. THE FIRST CFC TEAM MADE A SIGNIFICANT IMPACT ON THE FIELD OF GLAUCOMA AND HELPED TO TRANSFORM THE UNDERSTANDING OF GLAUCOMA FROM AN EYE DISEASE TO A NEURODEGENERATIVE DISEASE.TAKING THE FINDINGS FROM THE FIRST TEAM, A SECOND CFC TEAM WAS CREATED TO DEVELOP NEW BIOMARKERS TO DIAGNOSE AND MANAGE GLAUCOMA MORE EFFECTIVELY BEFORE VISION IS LOST AND OPEN PATHWAYS TO NEW TREATMENT OPTIONS FOR PATIENTS. A third CFC Team was launched to discover ways to restore vision lost to glaucoma by restoring, regenerating or replacing the retinal ganglion cells damaged in glaucoma.A fourth CFC team was launched to investigate common mechanisms of glaucoma and Alzheimer's to prevent and cure these and other neurodegenerative diseases. THE ORGANIZATION ALSO PROVIDES FUNDING FOR INNOVATIVE PILOT STUDIES IN GLAUCOMA RESEARCH. THESE INCUBATOR GRANTS ENABLE SCIENTISTS TO INVESTIGATE A NOVEL AND PROMISING IDEA AND GATHER CRITICAL DATA TO CONTINUE THEIR RESEARCH AND SECURE ADDITIONAL FUNDING. THIS PROGRAM CONTINUES TO NURTURE THE CAREERS OF PROMISING GLAUCOMA INVESTIGATORS AND BRING NEW IDEAS TO THE FIELD OF GLAUCOMA RESEARCH. IN ADDITION, THE ORGANIZATION SERVES AS A PRIMARY SOURCE OF INFORMATION AND SUPPORT FOR PATIENTS BY PROVIDING UNBIASED EDUCATIONAL MATERIALS IN PRINT AND ONLINE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Sign In — Free (10 views/day)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $6,473,014
Program Service Revenue $460,180
Investment Income $142,786
Other Revenue $112,167
TOTAL REVENUE $7,188,147

Expense Breakdown

Grants Paid $2,551,000
Salaries & Benefits $1,930,590
Fundraising Expenses $804,363
Program Expenses $5,950,391
Other Expenses $2,501,453
TOTAL EXPENSES $6,983,043

Year-over-Year Comparison

2023 2022 Change
Revenue $7,188,147 $6,480,467 +0.1%
Expenses $6,983,043 $6,158,927 +0.1%
Net Income $205,104 $321,540 -0.4%
Key Indicators
Grants to Organizations Grants to Individuals Lobbying Political Activity Foreign Activities Donor Advised Fund Schedule B Required
🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Sign In

Governance

Voting Members
16
Independent Members
15
Employees
12
Volunteers
30

Governance Policies

Conflict of Interest Policy
Whistleblower Policy
Document Retention Policy

Special Practices & Reported Activities

Operated a School
Operated a Hospital
Provided First Class Travel
Reported Conflict of Interest
Reported Asset Diversion
Excess Benefit Transaction
Made Political Expenditures
Engaged in Lobbying
Operated Donor Advised Fund
Maintained Art Collections
Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers
5
$287,531
Total Directors
16
$287,531
Key Employees
0
$0
Highest Compensated
0
reported
Name Title Hours/Week Role Reportable Comp Other Comp Total
THOMAS M BRUNNER President & CEO 24.00
Officer Director
$273,462 $14,069 $287,531
NANCY GRAYDON E.D. DEVEL. & COO 40.00
$255,241 $13,026 $268,267
ANDREW JACKSON DIR. COMMUNICATION 40.00
$149,731 $7,619 $157,350
CATALINA SAN AGUSTIN DIRECTOR OPERATION 40.00
$147,047 $7,481 $154,528
Morgan Velarde Dir. Philanthropic 40.00
$113,823 $5,779 $119,602
Maxson Thomas xxxxxxxxx 40.00
$113,292 $5,752 $119,044
ANDREW G IWACH MD CHAIR 5.00
Officer Director
$0 $0 $0
RUTH D WILLIAMS MD VICE CHAIR 5.00
Officer Director
$0 $0 $0
CHARLES R WILMOTH Treasurer 5.00
Officer Director
$0 $0 $0
Richard HALPRIN CPA Secretary 5.00
Officer Director
$0 $0 $0
FREDERICK H BRINKMANN Director 5.00
Director
$0 $0 $0
Nancy S Forster Director 5.00
Director
$0 $0 $0
Oluwatosin Smith Director 5.00
Director
$0 $0 $0
ROBERT L STAMPER MD Director 5.00
Director
$0 $0 $0
DENNIS E SINGLETON Director 5.00
Director
$0 $0 $0
LINDA C LINCK Director 5.00
Director
$0 $0 $0
ADRIENNE L GRAVES PHD Director 5.00
Director
$0 $0 $0
John G Flanagan PHD Director 5.00
Director
$0 $0 $0
Terri-Diann Pickering MD Director 5.00
Director
$0 $0 $0
David S Friedman Director 5.00
Director
$0 $0 $0
Tracy Valorie Director 5.00
Director
$0 $0 $0
Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year Revenue Expenses Assets Net Income
2025 No data No data No data No data
2024 $7,188,147 $6,983,043 $14,638,577 $205,104
2023 $6,480,467 $6,158,927 $14,426,054 $321,540
2022 $5,777,174 $4,937,400 $13,065,899 $839,774
2021 $4,401,477 $4,575,043 $13,366,326 $-173,566
2020 $5,829,191 $4,306,714 $12,305,821 $1,522,477
2019 $3,379,929 $4,071,705 $10,976,910 $-691,776
Explore More Nonprofits
Top 100 Nonprofits in California Largest U.S. Nonprofits Best Rated Nonprofits Most Efficient Nonprofits

Compare GLAUCOMA RESEARCH FOUNDATION with other nonprofits in California and across the country.